ArticleHepatobiliary surgery and nutrition2026
Impact of adjuvant therapy on survival outcomes in resected gallbladder cancer: a systematic review and meta-analysis.
Article in Hepatobiliary surgery and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gallbladder cancer (GBC) is the most common malignancy of the biliary tract and ranks as the fifth most prevalent cancer of the digestive system. Despite surgical resection, the prognosis for GBC remains dismal, marked by high recurrence rates and poor overall survival (OS). This meta-analysis investigates the impact of adjuvant therapies-including chemotherapy (CT), radiotherapy (RT), and chemoradiotherapy (CRT)-on the prognosis of resectable GBC, aiming to elucidate their clinical benefits. Methods: A thorough search of PubMed, Embase, and Web of Science databases was conducted up to April 2024. Studies assessing the effects of adjuvant therapies on OS and disease-free survival (DFS) in patients with resectable GBC were included. Statistical analyses were performed using STATA 17.0 software, with random-effect models employed to address heterogeneity. Results: The meta-analysis included 23 studies encompassing 36,214 patients. Adjuvant therapy was significantly associated with improved OS [hazard ratio (HR), 0.72; 95% confidence interval (CI): 0.66-0.78]. Specific types of adjuvant therapy showed distinct benefits: CT (HR, 0.80; 95% CI: 0.72-0.88), RT (HR, 0.76; 95% CI: 0.65-0.88), and CRT (HR, 0.56; 95% CI: 0.47-0.67). Subgroup analysis revealed a greater benefit in high-risk patients, including those with more severe tumor-node-metastasis (TNM) staging, R1 resection, and older age (HR, 0.62; 95% CI: 0.50-0.76). Conclusions: Adjuvant therapy significantly improves OS in patients with resectable GBC, with CRT offering the most substantial benefit. These results advocate for the inclusion of adjuvant therapy in treatment regimens, particularly for high-risk patients, and underscore the necessity for ongoing research to refine therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.